FDA Approves Pafolacianine for Lung Cancer Surgery

On December 16, 2022, the U.S. Food and Drug Administration (FDA) approved the targeted imaging agent pafolacianine for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors completely while sparing healthy tissue.

For more information, read the Penn Medicine press release. 

Posted 12/19/2022